Wall Street analysts expect Opko Health Inc. (NASDAQ:OPK) to post earnings per share (EPS) of ($0.08) for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Opko Health’s earnings. The lowest EPS estimate is ($0.09) and the highest is ($0.08). Opko Health also reported earnings of ($0.08) per share in the same quarter last year. The business is scheduled to announce its next quarterly earnings report on Wednesday, February 26th.
On average, analysts expect that Opko Health will report full year earnings of ($0.43) per share for the current fiscal year, with EPS estimates ranging from ($0.44) to ($0.42). For the next financial year, analysts forecast that the business will post earnings of ($0.27) per share, with EPS estimates ranging from ($0.38) to ($0.22). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Opko Health.
Opko Health (NASDAQ:OPK) last released its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02). The business had revenue of $228.80 million for the quarter, compared to the consensus estimate of $225.40 million. Opko Health had a negative return on equity of 14.42% and a negative net margin of 30.98%. During the same period in the previous year, the business posted ($0.05) earnings per share. Opko Health’s revenue was down 8.4% on a year-over-year basis.
Several research analysts recently issued reports on the stock. BidaskClub raised shares of Opko Health from a “sell” rating to a “hold” rating in a research report on Thursday, November 21st. Piper Jaffray Companies assumed coverage on Opko Health in a report on Monday, November 25th. They set an “overweight” rating and a $2.50 price objective on the stock. Zacks Investment Research upgraded Opko Health from a “hold” rating to a “buy” rating and set a $2.00 price objective on the stock in a research note on Friday, October 18th. Finally, Barrington Research reissued a “buy” rating and issued a $4.00 target price on shares of Opko Health in a report on Thursday, September 12th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $2.83.
Shares of Opko Health stock opened at $1.56 on Friday. The firm has a market cap of $1.06 billion, a P/E ratio of -6.24 and a beta of 2.20. The firm’s 50-day simple moving average is $1.64 and its 200-day simple moving average is $1.93. Opko Health has a twelve month low of $1.33 and a twelve month high of $3.93. The company has a debt-to-equity ratio of 0.14, a quick ratio of 0.90 and a current ratio of 1.08.
In other Opko Health news, Director Richard C. Pfenniger, Jr. purchased 25,000 shares of the firm’s stock in a transaction that occurred on Friday, October 25th. The shares were acquired at an average cost of $1.45 per share, for a total transaction of $36,250.00. Following the transaction, the director now directly owns 275,000 shares in the company, valued at $398,750. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Vice Chairman Jane Ph D. Hsiao purchased 400,000 shares of the firm’s stock in a transaction that occurred on Friday, October 25th. The shares were acquired at an average price of $1.50 per share, for a total transaction of $600,000.00. Following the completion of the transaction, the insider now owns 24,475,147 shares in the company, valued at $36,712,720.50. The disclosure for this purchase can be found here. Insiders have acquired 3,490,000 shares of company stock valued at $5,210,750 over the last quarter. Corporate insiders own 42.25% of the company’s stock.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Rhumbline Advisers raised its stake in shares of Opko Health by 10.8% in the third quarter. Rhumbline Advisers now owns 550,497 shares of the biotechnology company’s stock worth $1,151,000 after acquiring an additional 53,557 shares during the last quarter. Strs Ohio lifted its stake in shares of Opko Health by 7.5% during the second quarter. Strs Ohio now owns 323,200 shares of the biotechnology company’s stock valued at $788,000 after acquiring an additional 22,500 shares during the period. GABELLI & Co INVESTMENT ADVISERS INC. lifted its stake in shares of Opko Health by 100.0% during the second quarter. GABELLI & Co INVESTMENT ADVISERS INC. now owns 20,000 shares of the biotechnology company’s stock valued at $49,000 after acquiring an additional 10,000 shares during the period. First Republic Investment Management Inc. acquired a new position in shares of Opko Health during the second quarter valued at $115,000. Finally, JPMorgan Chase & Co. increased its position in Opko Health by 852.5% in the second quarter. JPMorgan Chase & Co. now owns 748,817 shares of the biotechnology company’s stock worth $1,662,000 after purchasing an additional 670,200 shares during the period. Hedge funds and other institutional investors own 21.61% of the company’s stock.
Opko Health Company Profile
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services.
Read More: How to invest in blue-chip stocks
Get a free copy of the Zacks research report on Opko Health (OPK)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.